相关实验视频

Updated: Jul 6, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

PD-1定义了Vδ1⁺ T细胞的一个独特的,功能性的,组织适应的状态,对癌症免疫治疗有影响

Daniel Davies^1,2, Shraddha Kamdar^1,2, Richard Woolf^1,3

¹Peter Gorer Department of Immunobiology, King's College London, London, UK.

|January 3, 2024

概括

检查点抑制疗法 (CPI) 向编程细胞死亡蛋白1 (PD-1) 在黑色素瘤中表现有前途. 内Vδ1+ gamma-delta T细胞可以预测对PD-1阻塞的反应,即使在低新抗原瘤中也是如此.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
T细胞生物学T细胞生物学

背景情况:

检查点抑制疗法 (CPI),特别是针对编程细胞死亡蛋白1 (PD-1),已经彻底改变了癌症治疗.
虽然对T细胞透的癌症有效,但CPI在逃避T细胞识别的癌症中的有效性不太清楚.
马-三角形 (γδ) T 细胞与这些具有挑战性的癌症类型有关,但PD-1 在这些细胞上的作用尚不清楚.

研究的目的:

在抗PD-1 CPI的背景下,研究PD-1表达在 γδ T 细胞上的功能相关性.
确定 γδ T 细胞标记能否预测黑色素瘤患者对 CPI 的反应.
描述表达Vδ1+ γδ T细胞的PD-1的转录组形状和功能状态.

主要方法:

分析内TRDV1转录作为黑色素瘤患者CPI反应的预测指标.
开发一种分离来自组织的Vδ1+ γδ T 细胞的协议.
与PD-1+ CD8+ αβ T细胞相比,对PD-1阳性 (PD-1+) Vδ1+ γδ T细胞进行转录组分析和功能分析.

主要成果:

内TRDV1转录显著预测了黑色素瘤患者的抗PD-1 CPI反应,特别是那些新抗原负载较低的患者.
与耗尽的PD-1+ CD8+ αβ T细胞相比,PD-1+ Vδ1+ γδ T细胞表现出不同的转录组程序.
这些PD-1+ Vδ1+ γδ T细胞保持了对PD-1阻塞敏感,对CPI有反应的效应器功能.

结论:

Vδ1+ γδ T 细胞是预测黑色素瘤中抗PD-1 CPI 疗效的潜在生物标志物.
在Vδ1+ γδ T细胞上PD-1表达不一定等同于耗尽;它们保留了功能能力.
向PD-1可能会增强Vδ1+ γδ T细胞的抗瘤活性,为瘤学提供新的治疗途径.

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...